FemtoMag, Inc. develops innovative biosensor technologies for medical diagnostics. The company specializes in advanced biosensor technologies targeting ultrasensitive quantitative detection of biomarkers for cancer diagnostics and treatment monitoring, infectious disease diagnostics, food safety, etc.
The primary focus of FemtoMag, Inc. R&D efforts is the development of innovative signal transducers for the detection and quantitation of magnetic nanoparticle reporters of biomolecular signals. Such magnetic reporters are attractive for reasons of their stability, low cost, and no technical issues such as sample turbidity, autofluorescence, photobleaching, and enzyme inhibitors. The technologies under development include giant magnetoresistive sensors, inductive sensors, and magnetoelectric sensors.
Recent successful R&D efforts resulted in an ultrasensitive quantitative biosensor platform, femtoMag, that integrates magnetic sensing into the ubiquitous lateral flow assay (LFA) format. The technology is 1-2 orders of magnitude more sensitive than commercial LFA that use gold nanoparticle reporters.